--- a
+++ b/clusters/9knumclustersv2/clust_1290.txt
@@ -0,0 +1,118 @@
+No known history of severe hypersensitivity reactions to any of the components of efatutazone or paclitaxel formulations
+Patients disease must not have micropapillary components
+Patient has a known hypersensitivity to any of the components of the study drug
+Known hypersensitivity to any of the components of nal-IRI, other liposomal products, fluoropyrimidines or leucovorin
+Known hypersensitivity to the components of MM-, or docetaxel
+Known hypersensitivity to any of the components of RO
+For Part B exclusively, known hypersensitivity to any of the components of trastuzumab
+For Part C exclusively, known hypersensitivity to any of the components of cetuximab
+Known allergy, hypersensitivity, or contraindication to paclitaxel, docetaxel, or irinotecan or any components used in their preparation
+Patients with known hypersensitivity to any of the components of CBL;
+Known hypersensitivity to the components of niraparib components or their formulation excipients
+Known hypersensitivity to ferumoxytol or any of its components
+History of, or known, hypersensitivity to any components of melphalan or the components of the Melphalan/HDS system.
+Any known hypersensitivity or contraindication to the components of the study drug AZD
+No known hypersensitivity or contraindication to the components of study treatment (M [VX-], gemcitabine)
+Any known hypersensitivity or contraindication to the components of the study drug AZD
+Patients with known hypersensitivity to any of the components of the PEGylated AuroShell suspension (polyethylene glycol, gold)
+Known hypersensitivity to any of the components of M or eribulin.
+Known hypersensitivity to any of the components of LMB- and/or SEL-
+Subject has known sensitivity and immediate hypersensitivity to any components of AMG  or conditioning regimen (cyclophosphamide and fludarabine).
+Known hypersensitivity to any of the components of cabozantinib or nivolumab
+Participants with prior use of pirfenidone or known hypersensitivity to any of the components of study treatment will be excluded from the study
+History of hypersensitivity to Vicinium or its components
+Patients must not have a known hypersensitivity to the components of niraparib or the excipients
+A known allergy or history of hypersensitivity to silicon, phosphorous or any of the OncoSil components
+Patients with a known history of hypersensitivity to lomustine, dacarbazine, or any components of lomustine
+Known hypersensitivity to any of the components of LMB-
+Known hypersensitivity to any of the components of LMB-
+Known hypersensitivity reactions to any of the components of Sym
+Patients with known allergy or hypersensitivity to selinexor, sorafenib or any of its components
+Known hypersensitivity to any of the components of talazoparib
+Patients with known allergy or hypersensitivity to nivolumab, ipilimumab, -azacytidine, or any of their components
+Known hypersensitivity to any of the products used in the trial  G-CSF (Neupogen, filgrastim), plerixafor (Mozobil), or any components of the chemotherapeutic agents or OBG/BCNU in vivo selection regimens
+Patients with known hypersensitivity to any of the components of PFK-.
+Known hypersensitivity to any of the components of MM- or other liposomal products
+Tumor with ?% IDC components
+Patient has known hypersensitivity to the components of study drug or its analogs
+Patients with known hypersensitivity to the components of study drug or its analogs
+Known hypersensitivity to enzalutamide or any of its components.
+Patients with a history of or known hypersensitivity to melphalan or the components of the Melphalan/HDS system.
+Have a history of hypersensitivity reaction to any of the components of Temozolomide
+Has known hypersensitivity to Cremophor EL, paclitaxel or its components.
+Any known hypersensitivity or contraindication to the components of the study drug AZD
+Known hypersensitivity to any of the components of talazoparib
+Any known hypersensitivity or contraindication to the components of the study drug AZD or olaparib.
+Have a known hypersensitivity to any of the components of AG-, matched placebo, or azacitidine.
+Known hypersensitivity to any of the components of tazemetostat
+Known hypersensitivity to any of the products used in the trial-G-CSF (Neupogen), plerixafor, or any planned components of conditioning regimens
+Known documented or suspected hypersensitivity to the components of the study drug(s) or analogs
+Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C
+Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C
+Known hypersensitivity to any of the components of talazoparib
+Known hypersensitivity to any of the components of RO and/or obinutuzumab
+Hypersensitivity to ASTX, excipients of the drug product, or other components of the study treatment regimen.
+Known hypersensitivity to any of the components of niraparib or prior hypersensitivity reactions to that class of drugs.
+Known hypersensitivity reaction to temozolomide or any of its components, or dacarbazine (DTIC) if enrolled on ARM  or irinotecan or any of its components if enrolled on ARM 
+Known hypersensitivity to any of the GTx- components or subjects previously received treatment with SARM
+Has known hypersensitivity to any of the components of IP.
+Subject has known hypersensitivity to immunoglobulins or any of the products or components to be administered during dosing.
+Known hypersensitivity to any of the components of MM-, other liposomal products, fluoropyrimidines or leucovorin
+Known hypersensitivity to the components of the study therapy or its analogs.
+Patients with known allergy or hypersensitivity to lirilumab, -azacytidine, or any of their components; patients who have previously been treated with lirilumab in combination with -azacytidine will be excluded
+Known hypersensitivity to any of the components of talazoparib
+Known serious reactions or hypersensitivity to any components of the UV vaccine or similar peptide based vaccines
+Known hypersensitivity to any of the components of talazoparib
+Known hypersensitivity to the components of niraparib
+Patients may not have a known allergy or hypersensitivity to any of the components of the investigational therapy, including polyethylene glycol (PEG) or topoisomerase inhibitors
+Subjects with known hypersensitivity to any of the components of AG-.
+Subjects with known hypersensitivity to any of the components of AG-.
+Known hypersensitivity to any components of the treatments
+Patients with a known hypersensitivity to any of the components of the drug products
+Patients with previous hypersensitivity reactions to the study drugs and components (ex: podophyllum and povidone).
+Hypersensitivity to one or more of the TL- active components
+History of hypersensitivity reactions to any components of the treatment regimen
+Any known hypersensitivity to ofatumumab or its components.
+Patient has known hypersensitivity to the components of study drug or its analogs
+Known hypersensitivity to any of the components of MM- or who have had hypersensitivity reactions to fully human monoclonal antibodies
+Patients with a known hypersensitivity to any of the components of the drug products
+Has a known hypersensitivity to the components of the study treatment or its analogs.
+Known hypersensitivity to cyclophosphamide, its metabolites or any other components, or known urinary outflow obstruction.
+Known hypersensitivity to any of the components of RO
+Patients with known hypersensitivity to any components of ME- or topotecan study drug product
+Any known hypersensitivity or contraindication to the components of study treatment
+Patients with known hypersensitivity to any of the components of AN- including doxorubicin and LH-RH agonists
+Subjects with known hypersensitivity to any components of ALKS 
+Subjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only)
+Known hypersensitivity to any of the treatment components of ramucirumab or LY.
+Known hypersensitivity to the components of niraparib
+Patient has a known hypersensitivity to any of the components of the study drug.
+Known hypersensitivity to HDAC inhibitors or to any of the components of mocetinostat
+Known hypersensitivity to any of the components of AG-
+Patients with known hypersensitivity to any of the components of romidepsin or who have had hypersensitivity reactions to paclitaxel
+Patients with a known or suspected hypersensitivity to any of the components of OTS.
+Known hypersensitivity to any components of SCLD. study drug product.
+Known significant hypersensitivity to any components of study treatment
+Patients with a known or suspected hypersensitivity to either gemcitabine or any of the components of PRI-.
+Hypersensitivity of AT or other components of the drug product
+Known hypersensitivity to the components of niraparib, PD- inhibitor, or their excipients
+Known hypersensitivity to the components of niraparib or excipients
+Known hypersensitivity to any of the components of PRI-
+Patients with a known hypersensitivity to any of the components of the drug products
+History of allergies or known hypersensitivity to any components of melphalan or the components of the Melphalan/HDS system
+Patients with known allergy or hypersensitivity to ponatinib, or -azacytidine, or any of their components
+Known hypersensitivity to any of the components of talazoparib
+Known or suspected hypersensitivity to any of the talazoparib capsule components.
+Known or suspected hypersensitivity to any of the talazoparib capsule components.
+Patient with known hypersensitivity to rocuronium, sugammadex or its components.
+Participants with known hypersensitivity to modafinil, armodafinil, or any of its components
+Patients with previous history of hypersensitivity to ribavirin or its components
+History of hypersensitivity to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in Lumason
+History of hypersensitivity to ribociclib or any of its components
+Patients with hypersensitivity to sonazoid or one of its components
+Hypersensitivity to CBT-, excipients of the drug product, or other components of the study treatment regimen.
+Known hypersensitivity to the study drug or components of the preparation
+Known hypersensitivity to Feraheme (ferumoxytol) or any of its components
+Any known hypersensitivity or contraindication to the components of study treatment
+Patients with known hypersensitivity to any of the components of PEGPH or cetuximab*
+Patients may not have a known hypersensitivity to any of the components of ganetespib